BACKGROUND: Though traditionally regarded as immunosuppressive, radiotherapy may also stimulate immune cells and facilitate an anti-tumor immune response. We therefore aimed to explore the prognostic significance of immune cell markers in non-small cell lung cancer (NSCLC) patients treated with postoperative radiotherapy (PORT). METHODS: In addition to demographic and clinicopathological information, tumor tissue samples were collected and tissue microarrays (TMAs) were constructed from 55 patients with stage I-IIIA NSCLC who received PORT. Tumor and stromal expression of CD1a+, CD3+, CD4+, CD8+, CD20+, CD56+, CD68+, CD117+ and CD138+ cells, as well as M-CSF and CSF-1R, was assessed by immunohistochemistry. RESULTS: In univariate analysis, high co-expression of CD4+ and CD8+ T lymphocytes as well as high expression of CD1a+ dendritic cells in the tumor stroma correlated with improved disease-specific survival (DSS). In multivariate analysis patients with stromal ↓CD4/↓CD8 expression had a hazard ratio of 21.1 (CI95% 3.9-115.6, P<0.001) when compared to those with ↑CD4/↑CD8 expression. CONCLUSIONS: Stromal ↓CD4/↓CD8 expression was an independent negative prognostic factor for survival in NSCLC patients receiving PORT, indicating a highly detrimental prognosis.
BACKGROUND: Though traditionally regarded as immunosuppressive, radiotherapy may also stimulate immune cells and facilitate an anti-tumor immune response. We therefore aimed to explore the prognostic significance of immune cell markers in non-small cell lung cancer (NSCLC) patients treated with postoperative radiotherapy (PORT). METHODS: In addition to demographic and clinicopathological information, tumor tissue samples were collected and tissue microarrays (TMAs) were constructed from 55 patients with stage I-IIIA NSCLC who received PORT. Tumor and stromal expression of CD1a+, CD3+, CD4+, CD8+, CD20+, CD56+, CD68+, CD117+ and CD138+ cells, as well as M-CSF and CSF-1R, was assessed by immunohistochemistry. RESULTS: In univariate analysis, high co-expression of CD4+ and CD8+ T lymphocytes as well as high expression of CD1a+ dendritic cells in the tumor stroma correlated with improved disease-specific survival (DSS). In multivariate analysis patients with stromal ↓CD4/↓CD8 expression had a hazard ratio of 21.1 (CI95% 3.9-115.6, P<0.001) when compared to those with ↑CD4/↑CD8 expression. CONCLUSIONS: Stromal ↓CD4/↓CD8 expression was an independent negative prognostic factor for survival in NSCLCpatients receiving PORT, indicating a highly detrimental prognosis.
Authors: Marta Usó; Eloísa Jantus-Lewintre; Silvia Calabuig-Fariñas; Ana Blasco; Eva García Del Olmo; Ricardo Guijarro; Miguel Martorell; Carlos Camps; Rafael Sirera Journal: Oncoimmunology Date: 2016-12-07 Impact factor: 8.110
Authors: John L Mikell; Theresa W Gillespie; William A Hall; Dana C Nickleach; Yuan Liu; Joseph Lipscomb; Suresh S Ramalingam; Raj S Rajpara; Seth D Force; Felix G Fernandez; Taofeek K Owonikoko; Rathi N Pillai; Fadlo R Khuri; Walter J Curran; Kristin A Higgins Journal: J Thorac Oncol Date: 2015-03 Impact factor: 15.609
Authors: Sigurd M Hald; Yury Kiselev; Samer Al-Saad; Elin Richardsen; Charles Johannessen; Marte Eilertsen; Thomas K Kilvaer; Khalid Al-Shibli; Sigve Andersen; Lill-Tove Busund; Roy M Bremnes; Tom Donnem Journal: BMC Cancer Date: 2015-05-29 Impact factor: 4.430
Authors: Marta Usó; Eloisa Jantus-Lewintre; Roy M Bremnes; Silvia Calabuig; Ana Blasco; Enrique Pastor; Irene Borreda; Sonia Molina-Pinelo; Luis Paz-Ares; Ricardo Guijarro; Miguel Martorell; Jerónimo Forteza; Carlos Camps; Rafael Sirera Journal: Oncotarget Date: 2016-08-16